CN107074826B - 用于治疗癌症的尿苷的二氧戊环类似物 - Google Patents

用于治疗癌症的尿苷的二氧戊环类似物 Download PDF

Info

Publication number
CN107074826B
CN107074826B CN201580056640.7A CN201580056640A CN107074826B CN 107074826 B CN107074826 B CN 107074826B CN 201580056640 A CN201580056640 A CN 201580056640A CN 107074826 B CN107074826 B CN 107074826B
Authority
CN
China
Prior art keywords
compound
alkyl
added
mixture
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580056640.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074826A (zh
Inventor
R·贝特尔
A·埃内罗特
B·克拉松
F·欧伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Priority to CN201911148331.9A priority Critical patent/CN110790789B/zh
Priority to CN202010199579.4A priority patent/CN111269264A/zh
Priority to CN201911149251.5A priority patent/CN110804072B/zh
Publication of CN107074826A publication Critical patent/CN107074826A/zh
Application granted granted Critical
Publication of CN107074826B publication Critical patent/CN107074826B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580056640.7A 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物 Active CN107074826B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201911148331.9A CN110790789B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN202010199579.4A CN111269264A (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911149251.5A CN110804072B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1450983-0 2014-08-25
SE1450983 2014-08-25
SE1550858 2015-06-22
SE1550858-3 2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en) 2014-08-25 2015-08-24 Dioxolane analogues of uridine for the treatment of cancer

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202010199579.4A Division CN111269264A (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911148331.9A Division CN110790789B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911149251.5A Division CN110804072B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物

Publications (2)

Publication Number Publication Date
CN107074826A CN107074826A (zh) 2017-08-18
CN107074826B true CN107074826B (zh) 2020-05-22

Family

ID=54014804

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580056640.7A Active CN107074826B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN202010199579.4A Pending CN111269264A (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911149251.5A Active CN110804072B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911148331.9A Active CN110790789B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202010199579.4A Pending CN111269264A (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911149251.5A Active CN110804072B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物
CN201911148331.9A Active CN110790789B (zh) 2014-08-25 2015-08-24 用于治疗癌症的尿苷的二氧戊环类似物

Country Status (24)

Country Link
US (7) US10144750B2 (enExample)
EP (2) EP3186244B1 (enExample)
JP (2) JP6663424B2 (enExample)
KR (2) KR102396905B1 (enExample)
CN (4) CN107074826B (enExample)
AU (2) AU2015308988C1 (enExample)
BR (1) BR112017003898B1 (enExample)
CA (2) CA2956251C (enExample)
CY (1) CY1122945T1 (enExample)
DK (2) DK3572410T3 (enExample)
EA (2) EA031106B1 (enExample)
ES (2) ES2927212T3 (enExample)
HR (1) HRP20201023T1 (enExample)
HU (2) HUE059640T2 (enExample)
IL (2) IL250344B (enExample)
MX (1) MX369649B (enExample)
MY (2) MY188089A (enExample)
NZ (2) NZ762628A (enExample)
PH (2) PH12017500184B1 (enExample)
PL (2) PL3186244T3 (enExample)
PT (2) PT3572410T (enExample)
SG (3) SG11201701172SA (enExample)
WO (1) WO2016030335A1 (enExample)
ZA (1) ZA201802864B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3572410T (pt) 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
MX386478B (es) * 2015-12-11 2025-03-18 Laurus Labs Ltd Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
CN109069509B (zh) * 2016-03-02 2020-10-16 麦迪维尔股份公司 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
EP3541824A1 (en) * 2016-11-18 2019-09-25 Neurovive Pharmaceutical AB Liver prodrugs of mitochondrial proton ionophores
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113402546A (zh) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
TW202200140A (zh) * 2020-04-15 2022-01-01 瑞典商米迪維艾克提伯拉公司 用於肝癌之miv-818/樂伐替尼(lenvatinib)組合療法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用
WO2025155547A1 (en) * 2024-01-17 2025-07-24 University Of Georgia Research Foundation, Inc. An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244799A (zh) * 1996-11-15 2000-02-16 耶鲁大学 L－β－二氧戊环尿苷类似物和治疗和预防病毒感染的方法
CN1471526A (zh) * 2000-10-13 2004-01-28 ϣ�����ﻯѧ�ɷ����޹�˾ 改善胞间传输的二氧戊环类似物
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
CN101534835A (zh) * 2006-09-01 2009-09-16 佐治亚大学研究基金会 用于癌症的L-OddC的前药

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
PL216525B1 (pl) * 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
AU2014354775A1 (en) * 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
PT3572410T (pt) * 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244799A (zh) * 1996-11-15 2000-02-16 耶鲁大学 L－β－二氧戊环尿苷类似物和治疗和预防病毒感染的方法
CN1471526A (zh) * 2000-10-13 2004-01-28 ϣ�����ﻯѧ�ɷ����޹�˾ 改善胞间传输的二氧戊环类似物
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents
CN101534835A (zh) * 2006-09-01 2009-09-16 佐治亚大学研究基金会 用于癌症的L-OddC的前药

Also Published As

Publication number Publication date
US10144750B2 (en) 2018-12-04
CA3128645C (en) 2023-06-27
US20230117570A1 (en) 2023-04-20
ES2796089T3 (es) 2020-11-25
CN110790789B (zh) 2023-05-12
US11447511B2 (en) 2022-09-20
IL250344B (en) 2020-01-30
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25
SG10202001117YA (en) 2020-04-29
US10654877B2 (en) 2020-05-19
AU2015308988A1 (en) 2017-02-23
PH12017500184A1 (en) 2017-06-28
AU2015308988B2 (en) 2018-04-26
EA201890648A3 (ru) 2019-02-28
PL3572410T3 (pl) 2022-10-03
CN110804072A (zh) 2020-02-18
PH12019501919A1 (en) 2020-09-14
EP3572410B1 (en) 2022-07-20
US20200239502A1 (en) 2020-07-30
JP6663424B2 (ja) 2020-03-11
PT3186244T (pt) 2020-05-29
EA201790328A1 (ru) 2017-08-31
HUE050705T2 (hu) 2020-12-28
SG10201911558UA (en) 2020-01-30
NZ762628A (en) 2023-04-28
US10336780B2 (en) 2019-07-02
US20190389890A1 (en) 2019-12-26
IL266766A (en) 2019-07-31
WO2016030335A1 (en) 2016-03-03
EA031106B1 (ru) 2018-11-30
SG11201701172SA (en) 2017-03-30
KR102398714B1 (ko) 2022-05-17
US20190100541A1 (en) 2019-04-04
EA201890648A2 (ru) 2018-08-31
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
KR20200035482A (ko) 2020-04-03
KR20170046736A (ko) 2017-05-02
MX2017002328A (es) 2017-05-22
MX369649B (es) 2019-11-15
KR102396905B1 (ko) 2022-05-13
US20170267705A1 (en) 2017-09-21
HRP20201023T1 (hr) 2020-10-16
IL250344A0 (en) 2017-03-30
CN111269264A (zh) 2020-06-12
JP2017526677A (ja) 2017-09-14
CA2956251C (en) 2022-10-25
JP6905609B2 (ja) 2021-07-21
AU2015308988C1 (en) 2018-09-06
EA033300B1 (ru) 2019-09-30
JP2020090535A (ja) 2020-06-11
PH12017500184B1 (en) 2017-06-28
US20210054008A1 (en) 2021-02-25
BR112017003898A2 (pt) 2017-12-05
EP3186244A1 (en) 2017-07-05
HUE059640T2 (hu) 2022-12-28
PL3186244T3 (pl) 2020-11-16
DK3186244T3 (da) 2020-07-13
BR112017003898B1 (pt) 2022-10-18
MY198325A (en) 2023-08-24
EP3572410A1 (en) 2019-11-27
AU2018201980A1 (en) 2018-04-12
US10822360B2 (en) 2020-11-03
CY1122945T1 (el) 2021-10-29
US20230382931A1 (en) 2023-11-30
ZA201802864B (en) 2019-07-31
CA3128645A1 (en) 2016-03-03
CN107074826A (zh) 2017-08-18
DK3572410T3 (da) 2022-08-29
AU2018201980B2 (en) 2019-05-16
ES2927212T3 (es) 2022-11-03
PT3572410T (pt) 2022-09-15
CA2956251A1 (en) 2016-03-03
EP3186244B1 (en) 2020-04-22
IL266766B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CN107074826B (zh) 用于治疗癌症的尿苷的二氧戊环类似物
HK40020872A (en) Dioxolane analogues of uridine for the treatment of cancer
HK40014377A (en) Dioxolane analogues of uridine for the treatment of cancer
HK40014376A (en) Dioxolane analogues of uridine for the treatment of cancer
TWI687431B (zh) 治療癌症之前藥
HK1235405A1 (en) Dioxolane analogues of uridine for the treatment of cancer
HK40014376B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40014377B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40011623B (en) Dioxolane analogues of uridine for the treatment of cancer
HK40011623A (en) Dioxolane analogues of uridine for the treatment of cancer
HK1235405B (zh) 用於治疗癌症的尿苷的二氧戊环类似物
HK1240591B (en) Dioxolane analogues of uridine for the treatment of cancer
HK1240591A1 (en) Dioxolane analogues of uridine for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1235405

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant